You are comparing tirzepatide vs retatrutide because you want the strongest medication available and you have read that retatrutide produced the larger numbers in trials. The honest answer has two parts. Retatrutide is still an investigational drug with no approval anywhere in the world and Eli Lilly has said it plans to submit an application to the FDA in the first quarter of 2027. Tirzepatide, sold as Zepbound for weight management, is approved and prescribed today, supported by completed trials and years of real-world use. Waiting is a real strategy. It also has costs that most people weighing it have never written down.
- Retatrutide is investigational: no FDA approval exists and Lilly has said it plans to file in the first quarter of 2027.
- Trial headlines reported up to 28.3% average weight loss for retatrutide at 80 weeks, but those are company announcements rather than peer-reviewed publications.
- Tirzepatide (Zepbound) is approved today and produced an average loss of more than 20% at the highest dose in SURMOUNT 1.
- Waiting has a price: cardiometabolic risk keeps compounding while a drug sits in review. An approval in 2027 does not mean a pharmacy has it in 2027.
- Choosing tirzepatide now does not close the retatrutide door. Our fee never changes with the molecule.
We write this as the clinicians' side of the question, because we hear it every week from adults who do not want a prescription from a stranger. They want to know whether the next molecule changes the decision in front of them today.
The direct answer
For someone who is a candidate for treatment today, tirzepatide is the medication that exists and retatrutide is the medication that might. That single sentence carries most of the decision. The regulatory record is not ambiguous: as of October 2026, retatrutide has no approval from the FDA, no approval from the EMA and no approved prescription pathway anywhere. Lilly completed its first Phase 3 obesity trial and reported positive topline results for two more in July 2026. The company said the same day that it plans to submit a Biologics License Application in the first quarter of 2027. A successful trial is not an approval. The FDA still has to receive and accept the application and then review it. Reviews of this length take many months.
Tirzepatide vs retatrutide
the facts as of October 2026
| Question | Tirzepatide (Zepbound) | Retatrutide |
|---|---|---|
| Approval status | FDA approved for chronic weight management | Investigational, Phase 3 only |
| Availability | Prescribed today, stocked by pharmacies | Cannot be legally prescribed or sold |
| Weight-loss data | More than 20% average at the highest dose over 72 weeks in SURMOUNT 1 | 28.3% average at 80 weeks in topline results, not yet peer reviewed |
| Safety record | Years of trial data and real-world use | Early, with full safety data still pending |
| Time to a prescription | Weeks, after a clinical evaluation | Unknown, measured in years |
| If you are accepted here | Billed by your pharmacy at its price, zero markup to you | Not available, so not a decision you can make today |
A table flattens one thing that matters: the two rows about data quality are not the same kind of evidence. Tirzepatide's number was published in a peer-reviewed journal after full review. Retatrutide's number arrived in a press release and will be presented at medical meetings and published later. We are not dismissing it. The result was strong and the program is real. We are saying that a decision about your body should rest on reviewed evidence where reviewed evidence exists.
What the retatrutide trials actually showed
Retatrutide is a triple agonist: it acts on the GLP-1, GIP and glucagon receptors at once, where semaglutide acts on one and tirzepatide on two. Lilly's Phase 3 program is called TRIUMPH. In the first trial, adults with obesity lost an average of 28.3% of their body weight at 80 weeks on the highest dose, according to the topline results Lilly announced in May 2026. In the trials announced in July 2026, adults with severe obesity and established cardiovascular disease lost an average of up to 22.6% at 80 weeks.
Those are meaningful numbers. Two cautions belong next to them. First, topline results are the company's own summary before the data has been published or reviewed by independent scientists. Second, averages describe the trial population and predict nobody in particular. The honest reading is that retatrutide looks like a genuine advance in the pipeline and that nobody, including Lilly, can tell you today when it reaches a pharmacy or what its final label will say.
What tirzepatide's data already establishes
Tirzepatide has the advantage of completed, reviewed evidence. In SURMOUNT 1, adults with obesity treated with the highest dose lost an average of more than 20% of their body weight over 72 weeks alongside diet and exercise. In STEP 1, the parallel semaglutide trial, the average was about 15%. These are trial averages and individual results vary, but they are the numbers an approved choice rests on, along with several years of prescribing experience and known safety monitoring.
There is a second, quieter advantage. Zepbound is a real product with real logistics. Doses exist at every step of titration, the supply has stabilized since the shortages of 2024 and 2025 and self-pay pricing is published. The alternative to starting treatment is more months of the status quo.
What waiting actually costs
The cost of waiting is invisible in a trial table and concrete in a life. The risks that a GLP-1 is prescribed to manage do not pause during a regulatory review. Blood pressure, A1c, ApoB, liver fat and joint load keep doing what they were doing. If weight is drifting up while you wait, the starting line in 2027 is worse than the starting line today.
Titration adds its own delay. GLP-1 treatment starts low and steps up over weeks, because that is how tolerability is built. Even if retatrutide were approved on schedule and stocked immediately, a person who begins in mid-2027 reaches a stable maintenance dose months after someone who began tirzepatide in late 2026. A year from now, the difference between the two paths is the molecule on one side and fourteen months of measured progress on the other.
There is also a financial caution worth naming. Any drug this anticipated attracts gray-market sellers long before approval. Compounded copies of approved GLP-1s were bad enough and the FDA has published its concerns about unapproved GLP-1 drugs used for weight loss. An investigational compound with no approved product has no legitimate supply chain at all. If someone offers you retatrutide today, they are selling you something with no lawful pathway to a pharmacy.
No clinician can promise a specific amount of weight loss from any medication. What measurement-based care can do is tell you, from your own labs and history, whether treatment is indicated and which approved option fits.
Why starting tirzepatide does not close the retatrutide door
The fear underneath the waiting question is usually this: if I start now and the better drug arrives, have I wasted my money and my time? The answer is no and it is worth seeing why. Treatment choices in this field are revisited as evidence matures. Switching molecules, under clinical supervision, with fresh labs and a deliberate plan, is a normal part of longitudinal care. Patients move from one approved GLP-1 to another today when history or response calls for it and a future switch to a newly approved agent would follow the same logic.
The financial architecture matters here too. If a platform earns its margin on the drug, every molecule change is also a chance to reprice you. We built our model the other way on purpose. One flat fee covers the doctor and the quarterly Biomarker Audit. Medication is billed by your pharmacy at its own price and we set nothing on it. The fee is the same whether you are on Zepbound, Wegovy, Ozempic, Mounjaro, Foundayo, a tablet or an injection. If retatrutide is someday approved and indicated for you, the molecule changes and our fee does not.
How we would make this decision with you
We do not think a choice like this should be made from a search results page, including from this article. It should be made the way our clinicians make it: labs first, conversation second, prescription only where indicated. Membership begins with a comprehensive Biomarker Audit every 90 days, four per year, run through the Beluga Health lab network. The panel includes ApoB, Lp(a), hs-CRP, HbA1c, lipids, insulin markers and full hormone and thyroid panels, because weight, blood sugar, lipids and hormones are one system and reading only one of them tells you a fraction of the story.
If the results and your history support medication, our clinicians prescribe branded, FDA-approved options only: Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo. We never prescribe compounded GLP-1s under any circumstance. Cash-pay tirzepatide is routed to Zepbound and Mounjaro fits insurance-covered type 2 diabetes, because the same molecule serves different label purposes.
What it costs, plainly
The Cardiometabolic Optimization Membership is $299 a month. There are no tiers. At sign-up, $598 is held on your card to cover the first two months combined. If a clinician cannot accept you into care, the hold is released and you are never charged. Once you are accepted, those first two months are non-refundable. From month three, the membership runs month to month at $299 with no long-term contract. A full year comes to $3,588.
What the fee buys is the clinical relationship: physicians licensed in all 50 states through Beluga Health, P.A., working under GoodLife Health's clinical protocols, plus the quarterly Biomarker Audit with every result in your hands. What the fee does not touch is medication. Your pharmacy bills it at its own price and that price is what you pay, with no markup, no molecule upcharge and no dose upcharge from us, ever. One flat fee for the doctor. Zero markup on the medicine.
The comparison with waiting, in money, is simple. Twelve months of membership plus a Zepbound self-pay vial costs about $299 a month for care plus $299 to $449 a month for medication as Lilly publishes it, which comes to roughly $7,200 to $9,000 across the year depending on dose. Twelve months of waiting costs the same zero in dollars and an unpriced amount in risk. We would not pretend to know what that second number is worth to you. We know it is not zero, because you would not be reading this if it were.
If you want the two approved injectables compared in clinical depth, read our guide to tirzepatide vs semaglutide for weight loss. For the fuller picture of what the membership includes, the definitive guide to Cardiometabolic Optimization is the reference we would hand you in the office.
FAQ
Is retatrutide FDA approved?
No. Retatrutide remains an investigational compound in Phase 3 testing. Eli Lilly reported positive topline results from its Phase 3 obesity trials in 2026 and said it plans to submit an application to the FDA in the first quarter of 2027. Approval is not guaranteed and no review timeline is confirmed.
How much weight did retatrutide cause in trials?
In topline results Lilly announced for its Phase 3 obesity program, adults on the highest dose lost an average of 28.3% of body weight at 80 weeks in the first trial and 22.6% at 80 weeks in the trial enrolling adults with severe obesity and established cardiovascular disease. These are company announcements rather than peer-reviewed publications. Individual results vary.
How much weight does tirzepatide cause?
In the SURMOUNT 1 trial, adults with obesity on the highest dose lost an average of more than 20% of body weight over 72 weeks alongside diet and exercise. Individual results vary and a trial average does not predict any one person's outcome.
Should I wait for retatrutide instead of starting Zepbound?
That depends on your health and your timeline and no article can decide it for you. What the record shows is that retatrutide cannot be prescribed today and may still be years away from pharmacies. Weight-related risks compound while you wait and tirzepatide is approved and available now. A clinician who measures first can tell you which choice fits your labs.
Can I switch from tirzepatide to retatrutide later?
Possibly, if it is approved and clinically appropriate, but that would be a fresh decision made with fresh labs. Nothing about starting tirzepatide today locks you out of a future option and our fee stays $299 a month whatever medication is indicated.
What does tirzepatide cost without insurance?
Lilly publishes self-pay pricing for Zepbound vials through LillyDirect at $299 to $449 a month depending on dose, as of 2026. Your pharmacy bills that price directly and we set nothing on it.
Does the GoodLife Health fee change if a stronger medication becomes available?
No. The fee is $299 a month whatever medication is clinically indicated and whatever the dose. There is no molecule upcharge and no dose upcharge, so a future switch changes nothing about the fee for your care.
Related Reading
- Tirzepatide vs semaglutide: which works better for weight loss?
- Retatrutide for weight loss: what patients should know
- Branded GLP-1 pass-through prices, explained
References
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (Eli Lilly press release, July 23 2026). 2026. investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Zepbound Self Pay Journey Program, LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings